Chemotherapy-induced thrombosis: A role for microparticles and tissue factor?

Seminars in Thrombosis and Hemostasis

Volumn 34, Issue 2, 2008, Pages 199-203

  Lechner, Daniel ^a   Weltermann, Ansgar ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Cancer; Chemotherapy; Microparticles; Thrombosis; Tissue factor

Indexed keywords

CISPLATIN; ETOPOSIDE; METHOTREXATE; THROMBOPLASTIN; VINCRISTINE;

CANCER CHEMOTHERAPY; CANCER PATIENT; CHEMOTHERAPY INDUCED THROMBOSIS; CLINICAL STUDY; DISEASE ASSOCIATION; DRUG INDUCED DISEASE; EVIDENCE BASED MEDICINE; HUMAN; HYPERCOAGULABILITY; IN VITRO STUDY; MEMBRANE MICROPARTICLE; PRIORITY JOURNAL; REVIEW; THROMBOSIS; TUMOR CELL;

ANTINEOPLASTIC AGENTS; BODY MASS INDEX; BREAST NEOPLASMS; CELL MEMBRANE STRUCTURES; HEMOSTASIS; HUMANS; LEUKOCYTE COUNT; PANCREATIC NEOPLASMS; PLATELET COUNT; RISK FACTORS; THROMBOEMBOLISM; THROMBOPLASTIN;

EID: 48749106856     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-2008-1079261     Document Type: Review

References (40)

1. Otten HM, Mathijssen J, ten Cate H, et al. Symptomatic venous thromboembolism in cancer patients treated with chemotherapy: an underestimated phenomenon. Arch Intern Med 2004;164:190-194
2. Sallah S, Wan JY, Nguyen NP. Venous thrombosis in patients with solid tumors: determination of frequency and characteristics. Thromb Haemost 2002;87:575-579
3. Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost 2007;5:632-634
4. Levine MN. Prevention of thrombotic disorders in cancer patients undergoing chemotherapy. Thromb Haemost 1997; 78:133-136
5. Dhami MS, Bona RD, Calogero JA, Hellman RM. Venous thromboembolism and high grade gliomas. Thromb Haemost 1993;70:393-396
6. Numico G, Garrone O, Dongiovanni V, et al. Prospective evaluation of major vascular events in patients with nonsmall cell lung carcinoma treated with cisplatin and gemcitabine. Cancer 2005;103:994-999
7. Khorana AA, Francis CW, Culakova E, Lyman GH. Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study. Cancer 2005;104: 2822-2829
8. Levine MN, Gent M, Hirsh J, et al. The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer. N Engl J Med 1988;318:404-407
9. Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 2008; 111:4902-4907
10. Lyman GH, Khorana AA, Falanga A, et al. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 2007;25:5490-5505
11. Paredes N, Xu L, Berry LR, Chan AK. The effects of chemotherapeutic agents on the regulation of thrombin on cell surfaces. Br J Haematol 2003;120:315-324
12. Aitokallio-Tallberg A, Viinikka L, Ylikorkala O. Urinary excretion of prostacyclin and thromboxane degradation products in patients with ovarian malignancy: effect of cytostatic treatment. Br J Cancer 1989;60:785-788
13. Walsh J, Wheeler HR, Geczy CL. Modulation of tissue factor on human monocytes by cisplatin and adriamycin. Br J Haematol 1992;81:480-488
14. Togna GI, Togna AR, Franconi M, Caprino L. Cisplatin triggers platelet activation. Thromb Res 2000;99:503-509
15. Bertomeu MC, Gallo S, Lauri D, Levine MN, Orr FW, Buchanan MR. Chemotherapy enhances endothelial cell reactivity to platelets. Clin Exp Metastasis 1990;8:511-518
16. Woodley-Cook J, Shin LY, Swystun L, Caruso S, Beaudin S, Liaw PC. Effects of the chemotherapeutic agent doxorubicin on the protein C anticoagulant pathway. Mol Cancer Ther 2006;5:3303-3311
17. Feffer SE, Carmosino LS, Fox RL. Acquired protein C deficiency in patients with breast cancer receiving cyclophosphamide, methotrexate, and 5-fluorouracil. Cancer 1989; 63:1303-1307
18. Kuzel T, Esparaz B, Green D, Kies M. Thrombogenicity of intravenous 5-fluorouracil alone or in combination with cisplatin. Cancer 1990;65:885-889
19. Liebman HA, Wada JK, Patch MJ, McGehee W. Depression of functional and antigenic plasma antithrombin III (AT-III) due to therapy with L-asparaginase. Cancer 1982; 50:451-456
20. Mewhort-Buist TA, Liaw PC, Patel S, Atkinson HM, Berry LR, Chan AK. Treatment of endothelium with the chemotherapy agent vincristine affects activated protein C generation to a greater degree in newborn plasma than in adult plasma. Thromb Res 2008; in press
21. Oner AF, Gurgey A, Kirazli S, Okur H, Tunc B. Changes of hemostatic factors in children with acute lymphoblastic leukemia receiving combined chemotherapy including high dose methylprednisolone and L-asparaginase. Leuk Lymphoma 1999;33:361-364
22. Lopez JA, Kearon C, Lee AY. Deep venous thrombosis. Hematology (Am Soc Hematol Educ Program) 2004;1:439-456
23. Falati S, Gross P, Merrill-Skoloff G, Furie BC, Furie B. Real-time in vivo imaging of platelets, tissue factor and fibrin during arterial thrombus formation in the mouse. Nat Med 2002;8:1175-1181
24. Giesen PL, Rauch U, Bohrmann B, et al. Blood-borne tissue factor: another view of thrombosis. Proc Natl Acad Sci U S A 1999;96:2311-2315
25. Sturk-Maquelin KN, Nieuwland R, Romijn FP, Eijsman L, Hack CE, Sturk A. Pro- and non-coagulant forms of non-cell-bound tissue factor in vivo. J Thromb Haemost 2003;1:1920-1926
26. Yu JL, Rak JW. Shedding of tissue factor (TF)-containing microparticles rather than alternatively spliced TF is the main source of TF activity released from human cancer cells. J Thromb Haemost 2004;2:2065-2067
27. Freyssinet JM. Cellular microparticles: what are they bad or good for? J Thromb Haemost 2003;1:1655-1662
28. Hron G, Kollars M, Weber H, et al. Tissue factor-positive microparticles: cellular origin and association with coagulation activation in patients with colorectal cancer. Thromb Haemost 2007;97:119-123
29. Tesselaar ME, Romijn FP, Van Der Linden IK, Prins FA, Bertina RM, Osanto S. Microparticle-associated tissue factor activity: a link between cancer and thrombosis? J Thromb Haemost 2007;5:520-527
30. Zwicker JI, Kos CA, Johnston KA, Liebman HA, Furie BC, Furie B. Cancer-associated thrombosis: tissue factor-bearing microparticles are associated with an increased risk of venous thromboembolic events in cancer patients. J Thromb Haemost 2007;5: (abstract O-M-005)
31. Licciardello JT, Moake JL, Rudy CK, Karp DD, Hong WK. Elevated plasma von Willebrand factor levels and arterial occlusive complications associated with cisplatin-based chemotherapy. Oncology 1985;42:296-300
32. Lechner D, Kollars M, Gleiss A, Kyrle PA, Weltermann A. Chemotherapy-induced thrombin generation via procoagulant endothelial microparticles is independent of tissue factor activity. J Thromb Haemost 2007;5:2445-2452
33. Weber H, Lechner D, Kollars M, Eichinger S, Kyrle PA, Weltermann A. Shedding of procoagulant microparticles from tumor cells after chemotherapy. Hämostaseologie 2007; 01: (abstract FV05)
34. Kim HK, Song KS, Park YS, Kim CM, Lee KR. Method comparison of flow cytometric assay of platelet microparticles and changes of platelet microparticles during cancer chemotherapy. Thromb Haemost 2002;87:547-548
35. Periard D, Boulanger CM, Eyer S, et al. Are circulating endothelial-derived and platelet-derived microparticles a pathogenic factor in the cisplatin-induced stroke? Stroke 2007;38:1636-1638
36. Simak J, Holada K, Vostal JG. Release of annexin V-binding membrane microparticles from cultured human umbilical vein endothelial cells after treatment with camptothecin. BMC Cell Biol 2002;3:11
37. Telgenhoff DJ, Aggarwal SK, Johnson BN. Histochemical and morphological identification of Kupffer cells activated by cisplatin. Anticancer Res 1999;19:1005-1010
38. Willekens FL, Werre JM, Kruijt JK, et al. Liver Kupffer cells rapidly remove red blood cell-derived vesicles from the circulation by scavenger receptors. Blood 2005;105:2141-2145
39. Falati S, Liu Q, Gross P, et al. Accumulation of tissue factor into developing thrombi in vivo is dependent upon microparticle P-selectin glycoprotein ligand 1 and platelet P-selectin. J Exp Med 2003;197:1585-1598
40. Levitan N, Dowlati A, Remick SC, et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore) 1999;78: 285-291